[{"id":"1a88a82a-3303-489f-8916-22ffac696e62","acronym":"CURATE","url":"https://clinicaltrials.gov/study/NCT05272709","created_at":"2022-03-09T12:52:43.513Z","updated_at":"2024-07-02T16:35:04.084Z","phase":"Phase 1/2","brief_title":"TT-702 in Patients With Advanced Solid Tumours.","source_id_and_acronym":"NCT05272709 - CURATE","lead_sponsor":"Cancer Research UK","biomarkers":" HER-2 • ER • PGR • MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" HER-2 positive • HR positive • MSI-H/dMMR • HER-2 negative • ER negative","tags":["HER-2 • ER • PGR • MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • MSI-H/dMMR • HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nubeqa (darolutamide) • TT-702"],"overall_status":"Recruiting","enrollment":" Enrollment 188","initiation":"Initiation: 01/19/2022","start_date":" 01/19/2022","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-05-13"}]